Protagonist Therapeutics, Inc. (PTGX) Q4 2018 Earnings Results

Protagonist Therapeutics Misses on EPS, Stock Up 1.59%

The earnings report indicates that Protagonist Therapeutics is still in the development phase, with no revenue reported. Despite missing on EPS, the stock rose by 1.59%, likely due to positive sentiment around their ongoing clinical trials and drug development efforts. Investors may be encouraged by management's focus on future milestones.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.57	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about their pipeline and future developments. They did not provide specific guidance for the upcoming quarters.

Management highlighted ongoing efforts in drug development and potential future milestones.

They emphasized the importance of upcoming clinical trials.

Protagonist Therapeutics Misses on EPS, Stock Up 1.59%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Misses on EPS, Stock Up 1.59%

Key numbers

Management commentary